Canadian Agency for Drugs and Technologies in Health

Canadian Agency for Drugs and Technologies in Health
Name	Canadian Agency for Drugs and Technologies in Health
Abbreviation	CADTH
Formation	1989
Type	Crown corporation
Headquarters	Ottawa, Ontario
Region served	Canada
Leader title	President and CEO

Canadian Agency for Drugs and Technologies in Health is a federally funded health technology assessment organization established to provide evidence-based information about pharmaceuticals, medical devices, and health technologies to provincial and territorial decision-makers including Ontario Ministry of Health, Alberta Health Services, and British Columbia Ministry of Health. It operates within the context of Canadian health policy debates involving stakeholders such as Health Canada, Patented Medicine Prices Review Board, Canadian Institute for Health Information, and provincial health ministries while interacting with international organizations including National Institute for Health and Care Excellence, Agency for Healthcare Research and Quality, European Medicines Agency, and World Health Organization. The agency produces systematic reviews, health technology assessments, and reimbursement advice used by payers like RAMQ, Manitoba Health, and hospital networks including Toronto General Hospital.

History

The agency traces roots to collaborative initiatives among Canadian provinces and territories in the late 1980s and early 1990s alongside organizations such as Canadian Institutes of Health Research, Fédération des médecins spécialistes du Québec, and the Canadian Medical Association to standardize evaluation of pharmaceuticals and medical devices. Early predecessors worked with bodies including Saskatchewan Health and Nova Scotia Health Authority on comparative effectiveness reviews prior to formal incorporation. Over time the agency engaged with international partners like NICE and Scottish Medicines Consortium to adapt methodologies from the United Kingdom and Scotland while responding to national policy instruments such as recommendations from the Romanow Commission and legislative frameworks influenced by Canada Health Act discussions.

Mandate and Functions

Mandate and functions include producing health technology assessments, conducting horizon scanning for forthcoming biologics, advising on drug reimbursement, and producing rapid reviews for stakeholders such as Pan-Canadian Pharmaceutical Alliance, Provincial/Territorial Health Ministers, and hospital procurement committees. The agency synthesizes evidence from clinical trials registered with ClinicalTrials.gov, regulatory decisions by Health Canada, pricing information from the Patented Medicine Prices Review Board, and economic models aligned with standards used by Institute for Clinical and Economic Review and Canadian Agency for Drugs and Technologies in Health peers internationally. Functions also encompass knowledge translation through workshops with organizations like Canadian Pharmacists Association, Canadian Nurses Association, and academic partners including University of Toronto and McGill University.

Organizational Structure

The organizational structure features a board of directors constituted by provincial and territorial representatives and stakeholder appointees drawn from institutions such as Public Health Agency of Canada and provincial health ministries. Operational divisions include the clinical effectiveness program, health economics unit, and evidence synthesis teams staffed by professionals recruited from universities like University of British Columbia, Université de Montréal, and research institutes such as Institute for Clinical Evaluative Sciences. Leadership roles interact with advisory committees composed of clinicians from Royal College of Physicians and Surgeons of Canada, patient representatives from groups like Canadian Cancer Society, and industry liaisons associated with Innovative Medicines Canada.

HTA Processes and Methodologies

HTA processes rely on systematic review standards used by Cochrane Collaboration, grading approaches akin to GRADE Working Group, and economic evaluation methods drawing on texts used at London School of Economics and Harvard School of Public Health. Methodologies cover randomized controlled trials indexed in Embase and MEDLINE (PubMed), observational evidence using frameworks from STROBE, diagnostic accuracy studies aligned with QUADAS-2, and modeling techniques similar to those applied by ISPOR. Processes include stakeholder input sessions with patient groups from Médecins Sans Frontières (Canada), clinician panels including members of Canadian Medical Association, and external peer review involving academics from McMaster University and University of Calgary.

Major Reports and Initiatives

Major reports have addressed oncology drug review processes relevant to Cancer Care Ontario, assessments of biosimilars used in immunology and oncology, and evaluations of digital health interventions such as telemedicine services implemented in Nunavut and northern communities. Initiatives include pan-Canadian collaboration with the Pan-Canadian Oncology Drug Review model, the establishment of rapid response services used during public health emergencies similar to work by Public Health Agency of Canada during influenza seasons, and methodological guidance documents influenced by international best practices from World Health Organization and European Network for Health Technology Assessment.

Partnerships and Stakeholder Engagement

Partnerships extend to provincial health ministries, academic health science centers such as St. Michael's Hospital, patient advocacy groups including Heart and Stroke Foundation of Canada, industry stakeholders like Pfizer Canada, and international HTA bodies such as INAHTA members. Stakeholder engagement mechanisms include public consultations, patient input frameworks modeled after Patient-Centered Outcomes Research Institute practices, and collaboration agreements with research networks such as Canadian Network for Observational Drug Effect Studies.

Impact and Criticism

Impact is seen in formulary decisions by entities such as Ontario Drug Benefit Program, cost-effectiveness thresholds referenced by provincial agencies, and decision support for procurement at hospitals like The Ottawa Hospital. Criticism centers on timeliness of reviews relative to regulatory approvals by Health Canada, perceived transparency compared with organizations like NICE, and challenges in incorporating real-world evidence from sources such as provincial drug databases maintained by Manitoba Health and Alberta Health. Debates also involve balancing input from industry associations like Innovative Medicines Canada against patient groups such as Canadian Cancer Society and clinical societies including Canadian Cardiovascular Society.

Category:Health technology assessment organizations